BNT162b2ワクチンの第2投与を遅らせた: 革新か誤った推測か?
John F R Robertson1, Herb F Sewell1, Marcia Stewart2
1Graduate Entry Medicine Division, Royal Derby Hospital, University of Nottingham, Derby DE22 3DT, UK.
Lancet (London, England)
|February 22, 2021
まとめ
No abstract available in PubMed .
関連する概念動画
Vaccinations
49.2K
Overview
49.2K
Bioavailability Study Design: Single Versus Multiple Dose Studies
78
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
78
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
115
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
115
Bioequivalence studies: Biowaivers
77
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
77


